ImmunoGen shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $9 to $22.
Portfolio Pulse from Benzinga Newsdesk
JP Morgan has upgraded ImmunoGen's stock from Neutral to Overweight and raised its price target from $9 to $22, leading to a rise in ImmunoGen's share prices.
September 13, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunoGen's stock has been upgraded by JP Morgan from Neutral to Overweight, with a price target increase from $9 to $22. This has resulted in a rise in the company's share prices.
The upgrade from JP Morgan, a major financial institution, is a strong positive signal for ImmunoGen. The increase in the price target from $9 to $22 indicates a significant upside potential, which is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100